Cabergoline - Hyperprolactinaemia
You are here : Home > Formulary Search > Cabergoline - Hyperprolactinaemia
Documentation
PAD Profile
Initiation and supply of at least one month of treatment before transfer of prescribing to primary care. Monitoring remains the responsibility of secondary care in line with position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology. https://pubmed.ncbi.nlm.nih.gov/30818417/
Other Indications
Below are listed other indications that Cabergoline is used to treat.
Other Drugs
Below are listed other drugs that are used to treat Hyperprolactinaemia.
Committee Recommendations (1)
The Surrey Heartlands Integrated Care System Area Prescribing Committee have agreed the following place in therapy for cabergoline and bromocriptine:
For the treatment of hyperprolactinaemic disorders
- BLUE traffic light classification for initiation by specialists for 1 month before transfer of prescribing responsibilities to primary care
- Cabergoline 1st line & Bromocriptine 2nd line
For the treatment of drug induced hyperprolactinaemia
- 1st line - select alternative medicine (to remove cause of drug-induced effect)
- Non-Formulary for cabergoline and bromocriptine
Suppression of lactation
- RED traffic light classification for cabergoline - as treatment should be part of obstetric care where necessary
- Non-Formulary for bromocriptine